1. Home
  2. SRFM vs GANX Comparison

SRFM vs GANX Comparison

Compare SRFM & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Surf Air Mobility Inc.

SRFM

Surf Air Mobility Inc.

HOLD

Current Price

$0.73

Market Cap

89.0M

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$1.85

Market Cap

88.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SRFM
GANX
Founded
2011
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Transportation Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
89.0M
88.6M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
SRFM
GANX
Price
$0.73
$1.85
Analyst Decision
Hold
Strong Buy
Analyst Count
3
4
Target Price
$3.25
$7.50
AVG Volume (30 Days)
1.9M
491.3K
Earning Date
05-11-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
45.69
31.46
EPS
N/A
N/A
Revenue
$106,557,000.00
$55,180.00
Revenue This Year
$25.90
N/A
Revenue Next Year
$20.72
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.63
$1.53
52 Week High
$6.17
$4.34

Technical Indicators

Market Signals
Indicator
SRFM
GANX
Relative Strength Index (RSI) 44.58 47.09
Support Level $0.66 $1.64
Resistance Level $0.86 $2.22
Average True Range (ATR) 0.06 0.13
MACD 0.00 -0.02
Stochastic Oscillator 27.81 16.56

Price Performance

Historical Comparison
SRFM
GANX

About SRFM Surf Air Mobility Inc.

Surf Air Mobility Inc is a regional air mobility platform operating commuter airlines in the United States and expanding an on-demand charter marketplace for passengers in the U.S. and globally. It is also focused on developing a proprietary aviation software, aircraft electrification powertrain technology and services to enable electrification across the regional air mobility sector. The company operates in a single reportable segment, Air Mobility. The Air Mobility segment derives revenue from operating scheduled commercial air service flights, which are sold to the public mainly on a per-seat basis; through subsidized EAS revenue awards from the Department of Transportation; and by operating on-demand flights for customers on an ad-hoc, by request basis.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Share on Social Networks: